Announcement PDF Racura Oncology Ltd • ABN 61 149 318 749 • L36 1 Macquarie Place Sydney NSW 2000 Australia T. +61 2 8051 3043 • E. info@racuraoncology.com • www.racuraoncology.com ASX Announcement Inside the Pipeline – Strategy, Science and Scale Racura Oncology Symposium, 24 March 2026, Sydney 4 March 2026 – Racura Oncology Limited (“Racura”) wishes to invite interested investors to attend an in-person Research & Development symposium at the Museum of Sydney on Tuesday, 24 March 2026 from 2.30pm. This event will provide investors with a detailed overview of the company’s science, clinical programs, and commercial strategy. Presentations will be delivered by senior members of the Racura leadership team, along with presentations from internationally recognised external scientific and clinical experts. The event will provide investors with a deeper understanding of the differentiated mechanism of action of (E,E)-bisantrene, the importance of the current clinical programs, and the commercialisation strategy of the company. Agenda • Opening Remarks • Session 1. The Science Behind the Company • Session 2. Clinical Program Overview • Session 3. Protecting Innovation, Delivering Milestones • Session 4. Q&A • Drinks & Canapes Event Details Date Tuesday, 24 March 2026 Formal Agenda 2.30pm – 5.00pm Networking Drinks 5.00pm – 6:30pm Venue Warrane Theatre, Museum of Sydney Corner of Bridge Street & Phillip St, Sydney NSW 2000 RSVP By Monday, 16 March 2026 via Eventbrite [ https://racuraoncology.eventbrite.com.au/ ] The Racura Oncology team looks forward to meeting all those who can join us. -ENDS- Racura Oncology Ltd • ABN 61 149 318 749 • L36 1 Macquarie Place Sydney NSW 2000 Australia T. +61 2 8051 3043 • E. info@racuraoncology.com • www.racuraoncology.com About Racura Oncology (ASX: RAC) Racura Oncology (ASX: RAC) is a Phase 3 stage clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care. Racura’s lead asset, (E,E)-bisantrene, is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent inhibition of the important cancer growth regulator MYC. (E,E)- bisantrene has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent discoveries made by Racura have enabled composition of matter IP filings that provide for 20 years of patent protection over (E,E)-bisantrene. Racura is advancing a proprietary formulation of (E,E)-bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a Phase 3 clinical program in acute myeloid leukaemia (AML), a Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients. Racura Oncology has collaborated with Astex, Emory University, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. Racura is actively exploring partnerships, licence agreements, or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world. Learn more at www.racuraoncology.com. If you have any questions on this announcement, or any past Racura Oncology announcements please visit our Interactive Announcements page. Racura encourages all investors to go paperless by registering their details with the Company’s share registry, Automic Registry Services, at www.automicgroup.com.au. Release authorised by: Daniel Tillett, CEO info@racuraoncology.com Media contact: Cherie Hartley +61 418 737 020 cherie.hartley@irdepartment.com.au